SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy
Authors:
- J. GrebelyJGJ. Grebely
- I.M. JacobsonIJI.M. Jacobson
- Z. KayaliZKZ. Kayali
- E.C. VernaEVE.C. Verna
- M.L. ShiffmanMSM.L. Shiffman
- R.H. HylandRHR.H. Hyland
- L.M. StammLSL.M. Stamm
- K.C. HuangKHK.C. Huang
- D.M. BrainardDBD.M. Brainard
- J.G. McHutchisonJMJ.G. McHutchison
- S. PolSPS. Pol
- R.T. ChungRCR.T. Chung
- 1 January 2017
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S513-S514